Current Drug Targeting using siRNAbased Nano Therapeutics for Pulmonary Diseases

Curr Pharm Des. 2022 Jul 27. doi: 10.2174/1381612828666220727144223. Online ahead of print.ABSTRACTThe importance of siRNA in nano drug delivery systems to target important pulmonary disorders such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and others is reviewed in this perspective. The great majority of lung illnesses are caused by protein misfolding. As a result, siRNA-based therapies are increasingly being used to target the gene. Given the difficulties of delivering bare siRNA, siRNA protection may ensure its efficacy in gene therapy. These issues could be solved with a nano-based siRNA delivery device. In this context, a siRNA-based nanocarrier for major pulmonary disorders has been explored.PMID:35894459 | DOI:10.2174/1381612828666220727144223

Source: Current Pharmaceutical Design - July 27, 2022 Category: Drugs & Pharmacology Authors: Venkateshwaran Krishnaswami Ruckmani Kandasamy Source Type: research